JP2024542158A5 - - Google Patents

Info

Publication number
JP2024542158A5
JP2024542158A5 JP2024527075A JP2024527075A JP2024542158A5 JP 2024542158 A5 JP2024542158 A5 JP 2024542158A5 JP 2024527075 A JP2024527075 A JP 2024527075A JP 2024527075 A JP2024527075 A JP 2024527075A JP 2024542158 A5 JP2024542158 A5 JP 2024542158A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
antibody
antibody according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527075A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542158A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/049142 external-priority patent/WO2023081471A1/en
Publication of JP2024542158A publication Critical patent/JP2024542158A/ja
Publication of JP2024542158A5 publication Critical patent/JP2024542158A5/ja
Pending legal-status Critical Current

Links

JP2024527075A 2021-11-05 2022-11-07 ヒト広域交差反応性インフルエンザモノクローナル抗体及びその使用方法 Pending JP2024542158A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163276374P 2021-11-05 2021-11-05
US63/276,374 2021-11-05
PCT/US2022/049142 WO2023081471A1 (en) 2021-11-05 2022-11-07 Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024542158A JP2024542158A (ja) 2024-11-13
JP2024542158A5 true JP2024542158A5 (https=) 2025-11-11

Family

ID=84541555

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527075A Pending JP2024542158A (ja) 2021-11-05 2022-11-07 ヒト広域交差反応性インフルエンザモノクローナル抗体及びその使用方法

Country Status (8)

Country Link
EP (1) EP4426730A1 (https=)
JP (1) JP2024542158A (https=)
KR (1) KR20250021396A (https=)
CN (1) CN118613502A (https=)
AU (1) AU2022383057A1 (https=)
CA (1) CA3237090A1 (https=)
IL (1) IL312538A (https=)
WO (1) WO2023081471A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023135067A1 (en) * 2022-01-13 2023-07-20 Basf Coatings Gmbh Tinted clearcoat composition and process of production such tinted clearcoat composition
WO2025117384A1 (en) * 2023-12-01 2025-06-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing influenza hemagglutinin stem-directed antibodies
WO2026021428A1 (en) * 2024-07-23 2026-01-29 Westlake University Anti-neuraminidase antibodies and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0279862B1 (en) 1986-08-28 1993-11-03 Teijin Limited Cytocidal antibody complex and process for its preparation
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1992000373A1 (en) 1990-06-29 1992-01-09 Biosource Genetics Corporation Melanin production by transformed microorganisms
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
WO1993006470A1 (en) 1991-09-17 1993-04-01 European Economic Community (Eec) Electron detector device for spectroscopic analyses of surfaces under x-ray excitation
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
AU2011373387B2 (en) * 2011-07-18 2017-06-29 Institute For Research In Biomedicine Neutralizing anti-influenza A virus antibodies and uses thereof
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device
KR102668588B1 (ko) 2015-04-08 2024-05-22 다나-파버 캔서 인스티튜트 인크. 인간화된 인플루엔자 모노클로날 항체 및 그의 사용 방법
BR112018072708A2 (pt) * 2016-05-05 2019-02-19 The Trustees Of The University Of Pennsylvania molécula de ácido nucleico, composição, e, método para tratar uma infecção por influenza em um sujeito.
EP3841110A1 (en) * 2018-08-23 2021-06-30 Vanderbilt University Human monoclonal antibodies to a new universal influenza a hemagglutinin head domain epitope

Similar Documents

Publication Publication Date Title
JP2024542158A5 (https=)
US11845805B2 (en) Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma
JP2021534797A5 (https=)
JP2018527887A5 (https=)
TW202104268A (zh) Cd73阻斷抗體
JP2021530960A5 (https=)
WO2013039954A1 (en) Anti-gitr antibodies
JP2018506964A (ja) 抗−cd47抗体及びその使用
US12076413B2 (en) Compositions and methods for modulating delta gamma chain mediated immunity
US20230192887A1 (en) Engineered anti-her2 bispecific proteins
JP2025501028A5 (https=)
TW202037365A (zh) 抗IL17a抗體的水性藥物組合物及其用途
US12606627B2 (en) α4β7 integrin binding proteins and methods of use
WO2024263900A2 (en) Il-23 antibody compositions and methods of use
TW202342095A (zh) 用於治療和預防covid—19之組成物
US20260028424A1 (en) Bispecific anti-c-kit and anti-cd203c antigen-binding molecules and uses thereof
TW202221025A (zh) 用於治療和預防covid—19的sars—cov—2抗體
CN112996540B (zh) 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途
WO2022111559A1 (zh) 双特异性抗体及其用途
US11981745B2 (en) Anti-mesothelin antigen-binding molecules and uses thereof
TW202132340A (zh) 治療白血病之方法
US20240109960A1 (en) Anti-il-9 antibodies and methods of use thereof
TW202513586A (zh) Tl1a結合蛋白及使用方法
WO2026050274A2 (en) April binding proteins, compositions, and methods of use thereof
TW202515910A (zh) Il-17抗體組合物及使用方法